Partial
Mostly Aligned
Patient Risk:
Moderate
Summary
Some statements about antibiotic-associated diarrhea/CDAD occurring with tigecycline are supported by the provided label excerpt (5.9), but many claims about relative incidence/frequency (nausea vs vomiting vs diarrhea), determinants of GI event rates (infection, concomitant drugs, baseline risk factors, duration/tolerability), and clinician response details are not supported by the supplied label text.
Category Scores
Accurate Statements
Antibiotic-associated colitis can be related to antibiotic use, including tigecycline.
5.9 Clostridioides difficile-Associated Diarrhea: CDAD has been reported with use of nearly all antibacterial agents, including TYGACIL, and may range from mild diarrhea to fatal colitis.
Any antibiotic can worsen diarrhea in a small number of patients.
5.9: CDAD reported with use of nearly all antibacterial agents (including TYGACIL).
If CDAD is suspected or confirmed, ongoing antibacterial drug use not directed against C. difficile may need to be discontinued.
5.9: 'If CDAD is suspected or confirmed, ongoing antibacterial drug use not directed against C. difficile may need to be discontinued.'
Unsupported Statements
Tigecycline commonly causes gastrointestinal (GI) adverse effects.
5.9 excerpt supports diarrhea/CDAD with TYGACIL but does not provide frequency language ('commonly') or a general GI adverse-effect frequency summary.
The incidence rates reported for GI events with tigecycline are generally highest for nausea and vomiting.
No incidence-rate or comparative frequency information for nausea vs vomiting vs other GI events is present in the supplied label excerpts.
Diarrhea and abdominal discomfort occur less often than nausea and vomiting but are still among the more frequently reported side effects of tigecycline.
No comparative frequency statements for diarrhea/abdominal discomfort relative to nausea/vomiting are present in the supplied excerpts.
The most frequent GI adverse reactions with tigecycline are nausea.
No 'most frequent' adverse reaction frequency data for nausea (or vomiting) is provided in the supplied excerpts.
The most frequent GI adverse reactions with tigecycline are vomiting.
No 'most frequent' adverse reaction frequency data for vomiting is provided in the supplied excerpts.
Diarrhea and other GI complaints occur at lower rates than nausea and vomiting, but still show up regularly in safety reporting for tigecycline.
No rate comparisons or 'regularly in safety reporting' language is present in the supplied excerpts.
GI event rates for tigecycline can vary depending on the underlying infection being treated.
The supplied excerpts do not describe GI event-rate variation by underlying infection.
GI event rates for tigecycline can vary depending on concomitant medications.
The supplied excerpts do not describe GI event-rate variation by concomitant medications.
GI event rates for tigecycline are especially affected by concomitant other antibiotics and chemotherapy.
No statement in the supplied excerpts specifies that other antibiotics/chemotherapy especially affect GI event rates.
GI event rates for tigecycline can vary depending on baseline GI risk factors, including prior intolerance to antibiotics.
No statements in the supplied excerpts link GI event-rate variation to baseline GI risk factors or prior intolerance to antibiotics.
GI event rates for tigecycline can vary depending on treatment duration and overall tolerability.
No statements in the supplied excerpts link GI event-rate variation to treatment duration or tolerability.
Any antibiotic can worsen diarrhea in a small number of patients.
The excerpt supports that CDAD has been reported with nearly all antibacterial agents, but it does not quantify the number of patients or use 'small number.'
Clinicians typically evaluate promptly if a patient develops severe, persistent diarrhea or signs of dehydration while taking an antibiotic.
The excerpt instructs that CDAD must be considered in patients who present with diarrhea following antibacterial drug use, but it does not include the 'typically evaluate promptly,' 'severe, persistent,' or 'signs of dehydration' phrasing.
Contradictions
Low
AI Statement
Clinicians consider stopping the drug depending on severity and workup when severe, persistent diarrhea or signs of dehydration occur in the setting of antibiotic use.
Label Reference
5.9 allows discontinuation of ongoing antibacterial drug use not directed against C. difficile if CDAD is suspected/confirmed, but the supplied excerpt does not support the specific conditioning on 'severity and workup' or 'signs of dehydration.'
Important Omissions
No discussion (in the evaluated claims) of the label’s specific CDAD time course ('over two months after the administration of antibacterial agents') or the label’s recommended management steps (fluid/electrolyte management, protein supplementation, CDAD-directed antibacterial drug treatment, surgical evaluation).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
While the excerpt supports CDAD/diarrhea risk with TYGACIL, unsupported claims about frequency rankings and patient-management details could mislead emphasis or clinical interpretation. However, there is no direct contraindication or dosing contradiction in the provided excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Mostly Aligned
Primary Issue
Several claims introduce comparative incidence/frequency and determinant factors for GI event rates that are not supported by the provided label excerpt(s).
Suggested Improvement
Limit statements to what the supplied label excerpt explicitly supports (CDAD with nearly all antibacterial agents including TYGACIL; CDAD must be considered in patients with diarrhea after antibacterial use; discontinuation of non–C. difficile-directed antibacterial therapy when CDAD is suspected/confirmed; and the label’s specific management guidance). Remove or qualify unsupported frequency rankings and determinants.